… COVID-19 patients. The current review aims to summarize actual therapeutic strategies …
COVID-19 and to examine the data supporting the potential benefits of SAC/VAL in COVID-19 …

… We estimated that following 5650 patients for a mean duration of 19 months would provide
… The unanticipated coronavirus disease 2019 pandemic prompted a protocol amendment for …

… In conclusion, the possibility that dual neprilysin inhibition and angiotensin II receptor
blockade could significantly augment levels of the protective peptide angiotensin(1–7), would …

… (ACEIs) and angiotensin II type‑1 receptor blockers (ARBs) … the use of AT1R-neprilysin
inhibitors (ARNIs) instead of ACEIs … receptor antagonists and mineralocorticoid receptor blockers. …

… coronavirus 2 — namely, infections of coronavirus disease-2019 (COVID-19) — and
neprilysin/AT1R inhibitor SAC/… AT1Rs required for ACE2 endocytosis in COVID-19 infections[27]. …

… renin-angiotensin-aldosterone system and COVID-19 infection. … inhibitors. The Canadian
Cardiovascular Society also recommended continuing angiotensin receptor neprilysin inhibitors…

… angiotensin converting enzyme into angiotensin II. Angiotensin II acts via angiotensin II type
1 receptor … can be counteracted via stimulating angiotensin II type 2 receptor. The second …

… In the present study, a series of 17 conventional angiotensin receptor blockers (ARBs),
including four novel bisartans (BisA–BisD) and two potent NEP antagonists, LBQ657 and …

… from vasoconstriction with angiotensin II to vasodilation with Mas receptor activation in
the … of COVID-19 is unclear but some animal data suggest a link. ACE2 and angiotensin (1-7) …

… The current results suggest that an angiotensin‐receptor neprilysin inhibitor can improve …
fraction versus angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, with …